We ask the Committee to discuss the proposed selective testing strategies for donations from individuals with a history of 1) malaria, 2) prior residence in a malaria-endemic country, and 3) travel to a malaria-endemic area by residents of nonendemic countries, and 4) in the event of local mosquito-borne malaria transmission in a geographic area of the U.S.

Points for the Committee to Consider:

1. Please comment on FDA’s proposed strategies for selectively testing blood donations from donors at risk for malaria using an FDA-licensed nucleic acid test (NAT).

2. Please comment on FDA’s proposal that blood establishments should implement time-limited NAT screening of all donations collected in area(s) of the U.S. when a single case of local mosquito-borne malaria is reported by public health authorities.